Compare FICO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | MIST |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 176.3M |
| IPO Year | 1995 | 2019 |
| Metric | FICO | MIST |
|---|---|---|
| Price | $1,226.04 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $1,689.92 | $8.00 |
| AVG Volume (30 Days) | 335.5K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 17.73 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.28 | $2,915.14 |
| Revenue Next Year | $16.97 | N/A |
| P/E Ratio | $69.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $870.01 | $1.00 |
| 52 Week High | $1,998.01 | $3.06 |
| Indicator | FICO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 35.20 |
| Support Level | $1,193.10 | $1.00 |
| Resistance Level | $1,593.96 | $2.01 |
| Average True Range (ATR) | 51.86 | 0.12 |
| MACD | 20.67 | -0.05 |
| Stochastic Oscillator | 79.77 | 9.02 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).